Highlights Longeveron Inc.

Equities

LGVN

US54303L2034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
1.09 ^USD	+4.81%		+4.81%	-91.99%

Jun. 03	Longeveron Launches Contract Manufacturing Business	MT
Jun. 03	Longeveron Inc. Announces Initiation of Work Under Its First Manufacturing Services Contract with Secretome Therapeutics	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Longeveron Launches Contract Manufacturing Business	Jun. 03	MT
Longeveron Inc. Announces Initiation of Work Under Its First Manufacturing Services Contract with Secretome Therapeutics	Jun. 03	CI
Longeveron Inc. Announces Launch of Contract Development and Manufacturing Business At the 15,000 Square Feet State-Of-The-Art Good Manufacturing Practice Facility	Jun. 03	CI
Earnings Flash (LGVN) LONGEVERON Posts Q1 Revenue $548,000	May. 14	MT
Longeveron Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Top Premarket Gainers	Apr. 08	MT
Longeveron to Effect 1-for-10 Reverse Stock Split	Mar. 20	MT
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	Jan. 29	CI
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B? in the Treatment of Mild Alzheimer?S Disease	Dec. 20	CI
Long-Term Survival Data from Longeveron?s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association	Nov. 11	CI
Earnings Flash (LGVN) LONGEVERON Posts Q3 Revenue $150,000	Nov. 10	MT
Longeveron Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B?? for the Treatment of Mild Alzheimer's	23-10-24	CI
Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer?s Disease	23-10-05	CI
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Earnings Flash (LGVN) LONGEVERON Reports Q2 Revenue $217,000	23-08-11	MT
Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B? in Hypoplastic Left Heart Syndrome	23-08-11	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
Longeveron Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Longeveron Inc.

Equities

LGVN

US54303L2034

Highlights

Filters